ArticleEJHaem2025
Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma.Allergy · 2026Article
- Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review.Dermatology and therapy · 2026Review
- Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland.Acta dermato-venereologica · 2026Article
- Association of Secondary Primary Malignancies in Cutaneous Lymphoma: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Little is known about long-term outcomes and causes of death for individuals with cutaneous T-cell lymphoma. Methods: We used SEER-18 registry data to examine outcomes among 9886 adults with mycosis fungoides (MF), Sézary syndrome (SS), primary cutaneous anaplastic large cell lymphoma (pcALCL), and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) diagnosed from 2000 to 2018. We calculated overall survival (Kaplan-Meier method), standardized mortality ratios (SMRs), absolute excess risk (AER) of death, and cumulative incidence of cause-specific mortality. Results: Individuals with CTCL were at increased risk of all-cause mortality relative to age-matched controls, with SMR ranging from 1.57 (95% CI: 1.49-1.65) in MF to 5.61 (95% CI: 4.65-6.7) in SS. This was true even for those who initially presented with early-stage disease. After a median follow-up of 64 months, the cumulative incidence of lymphoma-related death was 16.5%, compared to 10.5% other causes, 9.6% cardiovascular, 9.1% second primary malignancy, 1.8% infection, and 1.1% unknown cause. People diagnosed with CTCL were at higher risk of mortality due to leukemia and infectious causes than control populations, but secondary causes made overall minor contributions to total mortality. Conclusion: This population-level analysis revealed that individuals with CTCL were at increased risk of all-cause mortality relative to age-matched controls and that lymphoma remained a significant cause of death even in those presenting with early-stage disease. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.